Progenics: ASCO 2014 Meeting (Progenics) - Jun 4, 2014 - "In taxane-experienced mCRPC treated with PSMA ADC at doses of 2.3 mg/kg, reductions of PSA ≥30% are seen in ~36% and reductions of ≥50% are seen in ~15% of patients"; "CTC conversion from unfavorable to favorable occurs in ~45% of patients"; "PSMA expression both by IHC and CTC correlates well to PSA and CTC response"; "Low NE markers correlate well to PSA response with CTC reduction of >50% in 76% of patients"; "2.3 mg/kg is generally well tolerated and appears to be better tolerated than 2.5 mg/kg; most common AE’s are fatigue and neutropenia"; "A taxane-naïve cohort is ongoing" "
P2 data • Oncology • Prostate Cancer
|